These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 25201939)

  • 61. Similarities and differences between US and Japan as to pharmacogenomic biomarker information in drug labels.
    Otsubo Y; Asahina Y; Noguchi A; Sato Y; Ando Y; Uyama Y
    Drug Metab Pharmacokinet; 2012; 27(1):142-9. PubMed ID: 22201121
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The new US Food and Drug Administration pregnancy and lactation labeling rules: Their impact on clinical practice.
    Danesh MJ; Murase JE
    J Am Acad Dermatol; 2015 Aug; 73(2):310-1. PubMed ID: 26183972
    [No Abstract]   [Full Text] [Related]  

  • 63. Summaries of safety labeling changes approved by FDA-Boxed warnings highlights, January-March 2019.
    Am J Health Syst Pharm; 2019 Jun; 76(13):e8-e9. PubMed ID: 31361888
    [No Abstract]   [Full Text] [Related]  

  • 64. Consumers' Understanding of FDA Approval Requirements and Composite Scores in Direct-to-Consumer Prescription Drug Print Ads.
    O'Donoghue AC; Sullivan HW; Williams PA; Squire C; Betts KR; Fitts Willoughby J; Parvanta S
    J Health Commun; 2016 Aug; 21(8):927-34. PubMed ID: 27414000
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The need for contraception in patients taking prescription drugs: a review of FDA warning labels, duration of effects, and mechanisms of action.
    Zhang Z; Xu L; Zhang Z; Ding H; Rayburn ER; Li H
    Expert Opin Drug Saf; 2018 Dec; 17(12):1171-1183. PubMed ID: 30394114
    [No Abstract]   [Full Text] [Related]  

  • 66. Pharmacogenomic information in FDA-approved drug labels: Application to pediatric patients.
    Green DJ; Mummaneni P; Kim IW; Oh JM; Pacanowski M; Burckart GJ
    Clin Pharmacol Ther; 2016 Jun; 99(6):622-32. PubMed ID: 26693845
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The Drug Facts Box: Improving the communication of prescription drug information.
    Schwartz LM; Woloshin S
    Proc Natl Acad Sci U S A; 2013 Aug; 110 Suppl 3(Suppl 3):14069-74. PubMed ID: 23942130
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Some patients may receive too much information about prescriptions.
    Lavine G
    Am J Health Syst Pharm; 2009 Apr; 66(8):696-7. PubMed ID: 19336824
    [No Abstract]   [Full Text] [Related]  

  • 69. Pharmacogenomic information in the Warning section of drug labels: A comparison between labels in the United States and those in five other countries/regions.
    Imatoh T; Sai K; Saito Y
    J Clin Pharm Ther; 2018 Aug; 43(4):493-499. PubMed ID: 29682780
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Semantic processing to identify adverse drug event information from black box warnings.
    Culbertson A; Fiszman M; Shin D; Rindflesch TC
    AMIA Annu Symp Proc; 2014; 2014():442-8. PubMed ID: 25954348
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Written patient information on prescription drugs. The evolution of government and voluntary programs in the United States.
    Nightingale SL
    Int J Technol Assess Health Care; 1995; 11(3):399-409. PubMed ID: 7591542
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Placement and Format of Risk Information on Direct-to-Consumer Prescription Drug Websites.
    Sullivan HW; O'Donoghue AC; Rupert DJ; Willoughby JF; Aikin KJ
    J Health Commun; 2017 Feb; 22(2):171-181. PubMed ID: 28129069
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Physicians' Knowledge About FDA Approval Standards and Perceptions of the "Breakthrough Therapy" Designation.
    Kesselheim AS; Woloshin S; Eddings W; Franklin JM; Ross KM; Schwartz LM
    JAMA; 2016 Apr; 315(14):1516-8. PubMed ID: 27115269
    [No Abstract]   [Full Text] [Related]  

  • 74. Healthcare providers' use of a concise summary to prescribe for lactating patients.
    Koenig T; Robins C; Darby Lipman P; Dinatale M; Johnson T; Sahin L; Roca C; Limpert J; Baisden K; Mulugeta Y; Yao L; Jennings KA; Alimchandani M; Everett D; Gassman A; Chang C; Ellis C; Pfuma Fletcher E; Samuels S
    Res Social Adm Pharm; 2024 May; 20(5):531-538. PubMed ID: 38413289
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Survey of safety and efficacy information in drug inserts for topical prescription medications.
    Zaghi D; Maibach HI
    Am J Clin Dermatol; 2007; 8(1):43-6. PubMed ID: 17298106
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Changes coming to pregnancy labeling.
    Traynor K
    Am J Health Syst Pharm; 2015 Feb; 72(3):175-6. PubMed ID: 25596595
    [No Abstract]   [Full Text] [Related]  

  • 77. Changes to Pregnancy and Lactation Risk Labeling for Prescription Drugs.
    Fantasia HC; Harris AL
    Nurs Womens Health; 2015; 19(3):266-70. PubMed ID: 26058910
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Patient-perceived content and formatting expectations for prescription container labeling.
    Kebodeaux CD; Peters GL; Kindermann HA; Hurd PD; Berry TM
    J Am Pharm Assoc (2003); 2016; 56(3):242-247.e1. PubMed ID: 27067553
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Experimental evidence of consumer and physician detection and rejection of misleading prescription drug website content.
    Boudewyns V; Betts KR; Johnson M; Paquin RS; O'Donoghue AC; Southwell BG
    Res Social Adm Pharm; 2021 Apr; 17(4):733-743. PubMed ID: 32792323
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Quantitative Information on Oncology Prescription Drug Websites.
    Sullivan HW; Aikin KJ; Squiers LB
    J Cancer Educ; 2018 Apr; 33(2):371-374. PubMed ID: 27589969
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.